Available Until 9/17/2023

340B Drug Pricing - Update on Legislative, Regulatory and Political Landscape

NOTE: If you attended this live CE activity that was held during the 2020 NASP Virtual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-20-395-L04-P), you are ineligible to also receive CE credit for this home-study activity.

This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.


A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities

Activity Description

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). This activity was originally presented during the 2020 NASP Virtual Conference. This activity will discuss the 340B legal and regulatory landscape including manufacturer actions regarding contract pharmacies and other regulatory and agency developments. State and federal legislative activity including 340B discriminatory reimbursement, Matsui & Thune legislation, and federal drug pricing legislation will be covered. Faculty will also consider the implications of the 2020 election cycle.

Learning Objectives

The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:

  • Review current dynamics facing 340B covered entities and specialty pharmacies.
  • Describe state law updates on discriminatory reimbursement and mandator AAC billing.
  • Outline the federal drug pricing reform update.


Neil B. Minkoff
FountainHead HealthCare

Mark Ogunsusi, Esq., PharmD
Associate Attorney
Powers Pyles Sutter & Verville PC

Peggy Tighe
Principal, Government Relations/Legislative
Powers Pyles Sutter & Verville PC


It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. James Sheets is an employee of CSI Pharmacy. He is also a consultant for Evolves Biologics and received an honorarium. Mark Ogunsusi and Peggy Tighe have no relevant financial and/or commercial relationships to disclose. Neil Minkoff is a consultant for Avexis, Impel, UCB, Novartis, MAHP, AJMC, PRMA, ICON, and Concentric and receives honoraria or consulting fees.

CE Accreditation

Release Date: 9-17-2020
Expiration Date: 9-17-2023


This CE activity is jointly provided by ProCE, LLC and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-395-H04-P has been assigned to this knowledge-based home-study CE activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.


No external support has been received for this activity.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.